Summary of Jacobs Conference Call Company Overview - **Company**: Jacobs - **Industry**: Engineering and Construction Core Points and Arguments 1. **Progress in Redefining Asset Life Cycle**: Jacobs has made significant progress in redefining the asset life cycle, focusing on higher value services and early involvement in client decision-making processes. This shift has positively impacted financial results, marking one of the best quarters in recent history [6][7][8]. 2. **Backlog and Book-to-Bill Ratio**: The backlog is at record levels, with a Book-to-Bill ratio of 2.0 in the last quarter, rising from 1.2 to 1.4 over the trailing twelve months. The backlog is well-diversified, with 50% in critical infrastructure, 25% in life sciences and advanced manufacturing, and 25% in water and environmental sectors [12][13][14]. 3. **Revenue Guidance and Market Dynamics**: Jacobs raised its revenue guidance, with expectations for mid-single-digit growth. The pace of tech manufacturing jobs and a ramp-up in Q2 will influence whether they meet the higher end of guidance [15][16]. 4. **Data Center Business Growth**: The data center segment currently accounts for approximately 3-3.5% of revenues, growing rapidly. The scope of engagement has increased significantly, moving from design to comprehensive solutions including site selection and utility needs [26][30]. 5. **Sustainability of Growth in Key Markets**: The growth in life sciences and advanced manufacturing is deemed sustainable, with a 24-month visibility on pipeline compared to the previous 6-12 months. AI and drug discovery advancements are accelerating the market [23][24]. 6. **AI Integration and Digital Tools**: Jacobs has integrated AI into its operations, enhancing efficiency and client engagement. The use of AI-enabled platforms is driving growth and improving margins, particularly in water and life sciences sectors [40][41][42]. 7. **International Growth**: International business has outpaced domestic growth, particularly in Australia, New Zealand, and the Middle East. The UK market has also shown strength following political stabilization [76][77]. 8. **Capital Allocation Strategy**: Jacobs prioritizes organic growth and share repurchases, with a commitment to return at least 65% of free cash flow. The company has also increased its dividend by 12.5% year-on-year [86][87]. 9. **Industry Consolidation Outlook**: While sector-based consolidation is likely, Jacobs remains focused on organic growth opportunities. The company is not currently prioritizing large-scale M&A [81][82][86]. 10. **Long-term Margin Goals**: Jacobs aims to achieve adjusted EBITDA margins of 16%+ by fiscal 2029, driven by operating leverage, gross margin expansion, and an improved commercial mix [94][95]. Other Important Insights - **Client Relationships**: Jacobs emphasizes long-term client relationships and early involvement in projects, which has been beneficial in securing contracts [8]. - **Digital Transformation**: The company has invested in digital capabilities, enhancing its competitive position in the consulting space [57][60]. - **Market Positioning**: Jacobs is well-positioned in the energy and power sector, experiencing double-digit organic growth [89][91]. This summary encapsulates the key insights from the Jacobs conference call, highlighting the company's strategic direction, market performance, and future outlook.

Group 1: Company Performance - Jacobs reported a profit of $125.51 million for its fiscal first quarter 2026, compared to a loss of $18.13 million during the same period last year [9] - Revenue for the quarter reached $3.29 billion, reflecting a 12.3% increase from $2.93 billion a year ago [9] Group 2: Industry Trends - Construction demand for AI-related facilities is expected to continue growing, with a significant pipeline of work anticipated over the next 12 to 18 months across various markets, including the Middle East and Europe [2] - Pipeline growth in major verticals, such as life sciences and advanced manufacturing, increased by approximately 25%, while critical infrastructure work surged by more than 50% [2] Group 3: AI Integration - The company has doubled its AI efforts in development and consultancy, focusing on automating tasks and enhancing predictive analytics on-site [4] - The use of predictive analytics platforms like Acuity has been transformative, allowing the company to proactively address field-level issues in real time [5] Group 4: Project Focus - Key projects remain centered around data centers and semiconductor facilities, with owners often purchasing large electrical equipment directly while contracting Jacobs for integration [7] - There is also strong demand in the water sector, both domestically and internationally, with consistent gains in water-related construction bookings [8]

Summary of Nanobiotix Conference Call Company Overview - **Company**: Nanobiotix (NasdaqGS:NBTX) - **Industry**: Healthcare, specifically focused on oncology and CNS disorders through nanophysics-based therapeutics [1][2] Core Points and Arguments Nanobiotix's Unique Approach - Nanobiotix is pioneering nanophysics for healthcare, developing small objects that can trigger physical effects at the cellular level, impacting treatments for oncology and CNS disorders [2][3] - The company has three platforms: one for oncology, one for rethinking drug development, and one for CNS disorders [3] NBTXR3 Program - NBTXR3 is the most advanced program, currently in a Phase 3 study for head and neck cancer, with a partnership with Johnson & Johnson (J&J) [4] - The focus is on early-stage cancer treatment, where the majority of patients have local disease, representing a significant market opportunity [5][6] - NBTXR3 aims to enhance radiation therapy by improving the dose delivered to tumors while minimizing damage to surrounding healthy tissue [6][7] Market Opportunity - Approximately 60% of all cancer patients receive radiation therapy, with significant potential for NBTXR3 to impact around 160,000 patients in the EU5 and US for the initial indications [7][8] - The potential market size for NBTXR3 is estimated between $5 billion and $10 billion based on addressing 20% of the patient population [8] Partnership with J&J - The deal with J&J includes $2.6 billion in milestones and royalties ranging from low teens to low twenties percentage [8] - J&J is responsible for running three trials for NBTXR3, with the aim of broad commercialization [7][8] Clinical Data and Efficacy - In a Phase 1 study, NBTXR3 showed an 81% overall response rate and a 63% complete response rate among treated patients, with a median overall survival of 23 months [17][18] - The ongoing Phase 3 trial aims to improve progression-free survival (PFS) from nine months to 13 months, which could serve as registration data for the FDA [25] Future Directions - J&J has initiated a Phase 1 study for cisplatin-eligible head and neck cancer patients, indicating confidence in expanding the use of NBTXR3 [26] - The company is also exploring the use of NBTXR3 in lung cancer, where radiation therapy is widely used [29][30] Additional Important Content Other Platforms - Nanobiotix is developing Curadigm, a technology aimed at improving the delivery of various therapies by preventing their capture by the liver, thus enhancing systemic distribution [39][40] - The company is positioned to leverage its nanophysics-based approach beyond oncology, indicating potential for significant business development opportunities [39][40] Regulatory and Market Readiness - The transfer of the Phase 3 trial to J&J was completed in September 2025, with expected interim data in H1 2027 [24] - The company anticipates significant revenue from the J&J partnership, with plans for commercialization and recurrent revenue from royalties [38] This summary encapsulates the key points discussed during the Nanobiotix conference call, highlighting the company's innovative approach, market potential, partnership dynamics, and future directions in research and development.